What question did this study set out to answer?

To compare the prognostic performance and diagnostic agreement of blood-based mass spectrometry against standard bone marrow minimal residual disease assessments in patients with multiple myeloma.

August 19, 2026Blood

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results

View Full Paper

Ask AI

Bookmark

Authors

TDThomas DejoieCentre Hospitalier Universitaire de Nantes NRNeila RebouhCentre Hospitalier Universitaire de Nantes JCJill CorreCentre National de la Recherche Scientifique

Discussion

Member takes

Implication

Randomized trial subanalysis demonstrates serum mass spectrometry predicts survival in multiple myeloma, indicating blood tests can enable less invasive disease monitoring.

Key Points

To compare the prognostic performance and diagnostic agreement of blood-based mass spectrometry against standard bone marrow minimal residual disease assessments in patients with multiple myeloma.
Conducted a retrospective post-hoc analysis of 237 patients from the CASSIOPET companion study within the randomized CASSIOPEIA trial (NCT02541383).
Evaluated paired serum and bone marrow samples prospectively collected from post-induction through maintenance using serum mass spectrometry, next-generation flow cytometry, and next-generation sequencing.
Minimal residual disease (MRD) negativity across serum mass spectrometry, flow cytometry, and sequencing was associated with longer progression-free survival across all evaluated time points.
Serum mass spectrometry achieved high positive and negative predictive values compared to bone marrow testing at the 10⁻⁵ threshold during maintenance, though rule-out performance was lower compared to sequencing at 10⁻⁶.
Sustained MRD negativity at 1 and 2 years consistently identified patients with favorable outcomes across all three testing platforms.

Cite This Study

Dejoie et al. (2026) studied this question.

synapsesocial.com/papers/6a8563c403308d306e2d71be https://doi.org/10.1182/blood.2026033773

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial subanalysis demonstrates serum mass spectrometry predicts survival in multiple myeloma, indicating blood tests can enable less invasive disease monitoring.

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results

Discussion

Member takes

Implication

Key Points

Cite This Study

Blood-based MALDI-TOF mass spectrometry versus bone marrow MRD for monitoring multiple myeloma: CASSIOPEIA study results

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider